PCVX Stock Analysis: Buy, Sell, or Hold?
PCVX - Vaxcyte, Inc. Common Stock
$52.36
0.25 (0.48%)
▲
5d:
+5.65%
30d:
+10.49%
90d:
-6.4%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When PCVX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PCVX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PCVX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PCVX is currently trading at $52.36, which is considered extended relative to its 30-day fair value range of $46.92 to $51.12.
Technical Outlook: Technically, PCVX is in a downtrend. The price is approaching resistance at $53.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PCVX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $109.00 (+109.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PCVX is in a downtrend. The price is approaching resistance at $53.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PCVX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $109.00 (+109.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$46.92 -
$51.12
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 109.2% below Wall St target ($109.00)
Trading Range Analysis
30-Day Trading Range
$46.92 -
$51.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$45.30
Resistance Level
$53.48
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.02
Wall Street Target
$109.00
(+109.2%)
Share & Embed Analysis
Last updated: June 23, 2026 2:26 PM ET
Data refreshes hourly during market hours. Next update: 3:26 PM
Data refreshes hourly during market hours. Next update: 3:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCVX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Elvia Cowan
SELL
3000 shares
2026-04-07
Elvia Cowan
SELL
1892 shares
2026-03-17
Elvia Cowan
SELL
2500 shares
2026-03-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
